{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:56:29Z","timestamp":1779897389423,"version":"3.53.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:00:00Z","timestamp":1639008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jgar.2021.11.015","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T22:04:54Z","timestamp":1639605894000},"page":"8-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane\/tazobactam and ceftazidime\/avibactam"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0400-2092","authenticated-orcid":false,"given":"Wantin","family":"Sribenjalux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lumyai","family":"Wonglakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atibordee","family":"Meesing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.11.015_bib0001","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S1473-3099(19)30157-4","article-title":"Global burden of melioidosis in 2015: a systematic review and data synthesis","volume":"19","author":"Birnie","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2021.11.015_bib0002","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/tropicalmed3020038","article-title":"Melioidosis in Thailand: present and future","volume":"3","author":"Hinjoy","year":"2018","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.jgar.2021.11.015_bib0003","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(89)90768-X","article-title":"Halving of mortality of severe melioidosis by ceftazidime","volume":"334","author":"White","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2021.11.015_bib0004","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/520219","article-title":"Comparison of imipenem and ceftazidime as therapy for severe melioidosis","volume":"29","author":"Simpson","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.11.015_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003586","article-title":"Intravenous therapy duration and outcomes in melioidosis: a new treatment paradigm","volume":"9","author":"Pitman","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.jgar.2021.11.015_bib0006","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.1128\/AAC.05517-11","article-title":"Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in northeast Thailand","volume":"55","author":"Wuthiekanun","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.11.015_bib0007","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/121845","article-title":"Mohd Noor A. The in vitro antibiotic susceptibility of Malaysian isolates of Burkholderia pseudomallei","volume":"2013","author":"Ahmad","year":"2013","journal-title":"Int J Microbiol"},{"key":"10.1016\/j.jgar.2021.11.015_bib0008","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1995-7645(12)60050-9","article-title":"Ceftazidime resistance in Burkholderia pseudomallei: first report from India","volume":"5","author":"Behera","year":"2012","journal-title":"Asian Pac J Trop Med"},{"key":"10.1016\/j.jgar.2021.11.015_bib0009","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/cid\/ciy069","article-title":"Raising the stakes: loss of efflux pump regulation decreases meropenem susceptibility in Burkholderia pseudomallei","volume":"67","author":"Sarovich","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.11.015_bib0010","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.11.015_bib0011","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ijantimicag.2019.01.003","article-title":"Burkholderia pseudomallei acquired ceftazidime resistance due to gene duplication and amplification","volume":"53","author":"Chirakul","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.11.015_bib0012","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","article-title":"Infectious Diseases Society of America guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales, and Pseudomonas aeruginosa with difficult-to-teat resistance (DTR-P. aeruginosa)","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.11.015_bib0013","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1093\/jac\/dkw053","article-title":"Efficacy of ceftolozane\/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial","volume":"71","author":"Huntington","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.11.015_bib0014","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.11.015_bib0015","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2021.11.015_bib0016","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime\u2013avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.11.015_bib0017","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.11.015_bib0018","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime\u2013avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2021.11.015_bib0019","doi-asserted-by":"crossref","first-page":"e00103","DOI":"10.1128\/AAC.00103-18","article-title":"In vitro susceptibility of ceftolozane\u2013tazobactam against Burkholderia pseudomallei","volume":"62","author":"Chan","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.11.015_bib0020","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1128\/JCM.00935-07","article-title":"Accuracy of Burkholderia pseudomallei identification using the API 20NE system and a latex agglutination test","volume":"45","author":"Amornchai","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2021.11.015_bib0021","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.4269\/ajtmh.14-0025","article-title":"Evaluation of a latex agglutination assay for the identification of Burkholderia pseudomallei and Burkholderia mallei","volume":"90","author":"Tandhavanant","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jgar.2021.11.015_bib0022","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4269\/ajtmh.2002.66.759","article-title":"Short report: a rapid method for the differentiation of Burkholderia pseudomallei and Burkholderia thailandensis","volume":"66","author":"Anuntagool","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jgar.2021.11.015_bib0023","series-title":"Methods for antimicrobial dilution and disk susceptibility testing for infrequently isolated or fastidious bacteria; approved guideline","year":"2016"},{"key":"10.1016\/j.jgar.2021.11.015_bib0024","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4269\/ajtmh.17-0049","article-title":"Activity of ceftolozane\u2013tazobactam against Burkholderia pseudomallei","volume":"99","author":"Cronin","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jgar.2021.11.015_bib0025","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2021"},{"key":"10.1016\/j.jgar.2021.11.015_bib0026","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.cmi.2020.07.001","article-title":"Burkholderia pseudomallei multi-centre study to establish EUCAST MIC and zone diameter distributions and epidemiological cut-off values","volume":"27","author":"Karatuna","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2021.11.015_bib0027","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/IDR.S35529","article-title":"Development of ceftazidime resistance in an acute Burkholderia pseudomallei infection","volume":"5","author":"Sarovich","year":"2012","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2021.11.015_bib0028","doi-asserted-by":"crossref","first-page":"e00590","DOI":"10.1128\/AAC.00590-18","article-title":"In vitro susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patients to ceftazidime\u2013avibactam and ceftolozane\u2013tazobactam","volume":"62","author":"Van Dalem","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.11.015_bib0029","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/jgid.jgid_39_17","article-title":"Influence of biochemical features of Burkholderia pseudomallei strains on identification reliability by Vitek 2 system","volume":"10","author":"Zakharova","year":"2018","journal-title":"J Glob Infect Dis"},{"key":"10.1016\/j.jgar.2021.11.015_bib0030","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1099\/jmm.0.041525-0","article-title":"Misidentification of Burkholderia pseudomallei as Burkholderia cepacia by the VITEK 2 system","volume":"61","author":"Zong","year":"2012","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jgar.2021.11.015_bib0031","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0924-8579(02)00016-X","article-title":"A comparison of antibiotic susceptibility testing methods for cotrimoxazole with Burkholderia pseudomallei","volume":"19","author":"Piliouras","year":"2002","journal-title":"Int J Antimicrob Agents"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:58:12Z","timestamp":1761991092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521002745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":31,"alternative-id":["S2213716521002745"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.11.015","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane\/tazobactam and ceftazidime\/avibactam","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}